Results 41 to 50 of about 28,236 (118)

Navigating the chemical space of dipeptidyl peptidase-4 inhibitors

Drug Design, Development and Therapy, 2015
Watshara Shoombuatong,1 Veda Prachayasittikul,1,2 Nuttapat Anuwongcharoen,1 Napat Songtawee,1 Teerawat Monnor,1 Supaluk Prachayasittikul,1 Virapong Prachayasittikul,2 Chanin Nantasenamat1,2 1Center of Data Mining and Biomedical Informatics, 2Department ...
Shoombuatong W, Prachayasittikul V, Anuwongcharoen N, Songtawee N, Monnor T, Prachayasittikul S, Prachayasittikul V, Nantasenamat C   +7 more
doaj  

Alogliptin benzoate for management of type 2 diabetes

Vascular Health and Risk Management, 2015
Yoshifumi Saisho Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan Abstract: Dipeptidyl peptidase-4 (DPP-4) inhibitors, a new class of oral hypoglycemic agents, augment glucose-dependent insulin secretion and suppress ...
Saisho Y
doaj  

Association of Dipeptidiyl Peptidase-4 Inhibitors and Bullose Pemphigoid: A Report of Four Cases

Medeniyet Medical Journal
Dipeptidyl-peptidase 4 inhibitors (DPP4i) are commonly used as antidiabetic medications. Although these drugs are generally recognized for their favorable clinical safety profile, emerging evidence points to the potential for adverse events associated ...
Neslihan USLU, Kagan GUNGOR, Gonca TAMER, Bulent CAN   +3 more
doaj   +1 more source

Co-medications and dipeptidyl peptidase-4 inhibitors associated bullous pemphigoid, [PDF]

Anais Brasileiros de Dermatologia, 2022
Agoritsa Gravani, Panagiota Christou, Stelios Tigas, Ioannis D. Bassukas   +3 more
doaj   +1 more source

Health economic evaluation of dipeptidyl peptidase-4 inhibitors

Indian Journal of Endocrinology and Metabolism, 2011
Vishvas Garg
doaj   +1 more source

Experience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during Ramadan

Vascular Health and Risk Management, 2013
Anja Schweizer,1 Serge Halimi,2,3 Sylvie Dejager4 1Novartis Pharma AG, Basel, Switzerland; 2Department of Diabetology, Endocrinology and Nutrition, University Hospital of Grenoble, France; 3Joseph Fourier University, Grenoble, France; 4Novartis Pharma ...
Schweizer A, Halimi S, Dejager S
doaj  

Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease

Vascular Health and Risk Management, 2014
Peter P Toth1,2 1CGH Medical Center, Sterling IL, USA, 2Johns Hopkins University School of Medicine, Baltimore, MD, USA Abstract: Most individuals with type 2 diabetes mellitus have or will develop multiple independent risk factors for cardiovascular ...
Toth PP
doaj  

Hemoglobin Trajectories After Metformin Initiation Compared With Dipeptidyl Peptidase-4 Inhibitors: A Real-World Cohort Study. [PDF]

Cureus
Morita Y, Sakaguchi K, Asahara SI, Ogawa W, Sugawara K.   +4 more
europepmc   +1 more source

Target Trial of Glucagon-Like Peptide-1 Agonists versus Dipeptidyl Peptidase-4 Inhibitors and Mortality in Hemodialysis. [PDF]

Kidney Int Rep
Le D, Kilpatrick M, Kraft WK, Grams ME, Jaar BG, Shin JI.   +5 more
europepmc   +1 more source

Dipeptidyl peptidase-4 inhibitors are associated with a lower risk of osteoarthritis in patients with type 2 diabetes. [PDF]

Ther Adv Musculoskelet Dis
Chen YH, Byers Kraus V, Chang YS, Lin TM, Lee HY, Chang CK, Kuo TT, Chen JH, Chang CC.   +8 more
europepmc   +1 more source